09/ 966,960

Welcome to STN International! Enter x:x

LOGINID:ssspta1202txn

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2		"Ask CAS" for self-help around the clock
NEWS 3	Jun 03	New e-mail delivery for search results now available
NEWS 4	Aug 08	PHARMAMarketLetter(PHARMAML) - new on STN
NEWS 5	Aug 19	Aquatic Toxicity Information Retrieval (AQUIRE) now available on STN
NEWS 6	Aug 26	Sequence searching in REGISTRY enhanced
NEWS 7	Sep 03	JAPIO has been reloaded and enhanced
NEWS 8	Sep 16	Experimental properties added to the REGISTRY file
NEWS 9	Sep 16	CA Section Thesaurus available in CAPLUS and CA
NEWS 10	Oct 01	CASREACT Enriched with Reactions from 1907 to 1985
NEWS 11	Oct 24	BEILSTEIN adds new search fields
NEWS 12	Oct 24	Nutraceuticals International (NUTRACEUT) now available on STN
NEWS 13	Nov 18	DKILIT has been renamed APOLLIT
NEWS 14	Nov 25	More calculated properties added to REGISTRY
NEWS 15	Dec 04	CSA files on STN
NEWS 16	Dec 17	PCTFULL now covers WP/PCT Applications from 1978 to date
NEWS 17	Dec 17	TOXCENTER enhanced with additional content
NEWS 18	Dec 17	Adis Clinical Trials Insight now available on STN
NEWS 19	Jan 29	Simultaneous left and right truncation added to COMPENDEX, ENERGY, INSPEC
NEWS 20	Feb 13	CANCERLIT is no longer being updated
NEWS 21	Feb 24	METADEX enhancements
NEWS 22	Feb 24	PCTGEN now available on STN
NEWS 23	Feb 24	TEMA now available on STN
NEWS 24	Feb 26	NTIS now allows simultaneous left and right truncation
NEWS 25	Feb 26	PCTFULL now contains images
NEWS 26	Mar 04	SDI PACKAGE for monthly delivery of multifile SDI results
NEWS 27	Mar 20	EVENTLINE will be removed from STN
NEWS 28	Mar 24	PATDPAFULL now available on STN
NEWS 29	Mar 24	Additional information for trade-named substances without structures available in REGISTRY
NEWS 30	Apr 11	Display formats in DGENE enhanced
NEWS 31	Apr 14	MEDLINE Reload
NEWS 32	Apr 17	Polymer searching in REGISTRY enhanced
NEWS 33	Jun 13	Indexing from 1947 to 1956 added to records in CA/CAPLUS
NEWS 34	Apr 21	New current-awareness alert (SDI) frequency in WPIDS/WPINDEX/WPIX
NEWS 35	Apr 28	RDISCLOSURE now available on STN
NEWS 36	May 05	Pharmacokinetic information and systematic chemical names added to PHAR
NEWS 37	May 15	MEDLINE file segment of TOXCENTER reloaded
NEWS 38	May 15	Supporter information for ENCOMPPAT and ENCOMPLIT updated
NEWS 39	May 16	CHEMREACT will be removed from STN
NEWS 40	May 19	Simultaneous left and right truncation added to WSCA
NEWS 41	May 19	RAPRA enhanced with new search field, simultaneous left and right truncation
NEWS 42	Jun 06	Simultaneous left and right truncation added to CBNB
NEWS 43	Jun 06	PASCAL enhanced with additional data

09/ 966,960

```
 NEWS EXPRESS  April 4 CURRENT WINDOWS VERSION IS V6.01a, CURRENT
               MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP),
               AND CURRENT DISCOVER FILE IS DATED 01 APRIL 2003
 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS INTER    General Internet Information
 NEWS LOGIN    Welcome Banner and News Items
 NEWS PHONE    Direct Dial and Telecommunication Network Access to STN
 NEWS WWW      CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

  * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 14:57:09 ON 17 JUN 2003

=> file reg
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                       0.21       0.21

FILE 'REGISTRY' ENTERED AT 14:57:18 ON 17 JUN 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   16 JUN 2003  HIGHEST RN 532194-47-1
DICTIONARY FILE UPDATES:  16 JUN 2003  HIGHEST RN 532194-47-1

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2003

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

Crossover limits have been increased.  See HELP CROSSOVER for details.

Experimental and calculated property data are now available.  See HELP
PROPERTIES for more information.  See STNote 27, Searching Properties
in the CAS Registry File, for complete details:
http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf

=>
Uploading 09966960.str

L1      STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
'1L ' IS NOT A VALID STRUCTURE FORMAT KEYWORD
Structure Formats
SIA ----- Structure Image, Attributes, and map table if it contains
          data.  (Default)
SIM ----- Structure IMage.
SAT ----- Structure ATtributes and map table if it contains data.
```

09/ 966,960

SCT ----- Structure Connection Table and map table if it contains data.
SDA ----- All Structure DAta (image, attributes, connection table and map table if it contains data).
NOS ----- NO Structure data.
ENTER STRUCTURE FORMAT (SIM), NOS:sim
L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1 ful
FULL SEARCH INITIATED 14:58:00 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 363 TO ITERATE

100.0% PROCESSED 363 ITERATIONS 64 ANSWERS
SEARCH TIME: 00.00.01

L2 64 SEA SSS FUL L1

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	148.15	148.36

FILE 'CAPLUS' ENTERED AT 14:58:07 ON 17 JUN 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 17 Jun 2003 VOL 138 ISS 25
FILE LAST UPDATED: 16 Jun 2003 (20030616/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l2
L3 5 L2

=> d l3 1- ibib abs hitstr
YOU HAVE REQUESTED DATA FROM 5 ANSWERS - CONTINUE? Y/(N):y

L3 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2002:940240 CAPLUS
DOCUMENT NUMBER: 137:389011
TITLE: Preparation of phenyloxamic acid derivs. for treating hair loss
INVENTOR(S): Kukkola, Paivi Jaana
PATENT ASSIGNEE(S): Novartis AG, Switz.
SOURCE: Brit. UK Pat. Appl., 51 pp.
CODEN: BAXXDU
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
GB 2374009	A1	20021009	GB 2002-3060	20020208

PRIORITY APPLN. INFO.: US 2001-268131P P 20010212
OTHER SOURCE(S): MARPAT 137:389011
GI



I

AB A method of treating hair loss in a mammal comprises administering a compd. an phenyloxamic acid or derivs. (I, e.g., R = H, halo, OH, alkoxy; R1 = OH, alkoxy; R2, R3 = H, halo, CF3, cyano; R4 = alkyl, aryl; R5,R6, R7 = H, alkyl, cycloalkyl, or aryl; R5+R6 = alkylene interrupted by O, S, S:O, SO2, n= 0 or 1-4; W = O,S, or S:O , X = SR4, SOR4 or SO2R4; Y = O or H2; Z = H, halo or OH). Thus, N-{4-[3-(2,2-Dimethylpropylsulfamoyl)-4-hydroxyphenoxy]-3,5-dimethylphenyl}oxamic acid was prepd. in a series of reactions starting from 3,5-dimethyl-4-(4'-methxoyphenoxy)nitrobenzene (II). A topical compn. contained II 1, EtOH 60, propylene glycol 20, and di-Me isosorbide 19%.

IT **298695-13-3P 298695-14-4P**
RL: COS (Cosmetic use); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of phenyloxamic acid derivs. for treating hair loss)

RN 298695-13-3 CAPLUS
CN Propanoic acid, 3-[[4-[3-[(4-fluorophenyl)sulfonyl]-4-hydroxyphenoxy]-3,5-dimethylphenyl]amino]-3-oxo- (9CI) (CA INDEX NAME)



RN 298695-14-4 CAPLUS
CN Butanoic acid, 4-[[4-[3-[(4-fluorophenyl)sulfonyl]-4-hydroxyphenoxy]-3,5-

dimethylphenyl]amino]-4-oxo- (9CI) (CA INDEX NAME)



L3 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2002:314754 CAPLUS
DOCUMENT NUMBER: 136:335247
TITLE: Compositions for treatment of conditions assocd. with elevated Lp(a) levels using a thyromimetic compd. combined with a statin
INVENTOR(S): Steele, Ronald Edward; Dardik, Beatriz N.
PATENT ASSIGNEE(S): Novartis A.-G., Switz.; Novartis-Erfindungen Verwaltungsgesellschaft m.b.H.
SOURCE: PCT Int. Appl., 57 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002032408	A2	20020425	WO 2001-EP12075	20011018
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002023626	A5	20020429	AU 2002-23626	20011018

PRIORITY APPLN. INFO.: US 2000-242036P P 20001020
WO 2001-EP12075 W 20011018

OTHER SOURCE(S): MARPAT 136:335247

AB Disclosed are methods for the treatment of conditions assocd. with elevated levels of Lp(a), such as coronary heart disease (CHD), ischemic stroke, restenosis after angioplasty, peripheral vascular disease, intermittent claudication, redn. in necrosis after myocardial infarction, dyslipidemia and post-prandial lipemia. The methods include administration of a therapeutically effective amt. of a pharmaceutical combination of a thyromimetic compd. and a statin.

IT **298695-13-3 298695-14-4**
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(compns. for treatment of conditions assocd. with elevated Lp(a) levels using a thyromimetic compd. combined with a statin)

RN 298695-13-3 CAPLUS
CN Propanoic acid, 3-[[4-[3-[(4-fluorophenyl)sulfonyl]-4-hydroxyphenoxy]-3,5-dimethylphenyl]amino]-3-oxo- (9CI) (CA INDEX NAME)



RN 298695-14-4 CAPLUS
CN Butanoic acid, 4-[[4-[3-[(4-fluorophenyl)sulfonyl]-4-hydroxyphenoxy]-3,5-dimethylphenyl]amino]-4-oxo- (9CI) (CA INDEX NAME)



L3 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2002:294258 CAPLUS
DOCUMENT NUMBER: 136:325327
TITLE: Preparation of thyromimetic oxamic acids
INVENTOR(S): Kukkola, Paivi Jaana
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 29 pp., Cont.-in-part of U.S. Ser. No. 533,219.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002045751	A1	20020418	US 2001-966960	20010928
US 2002107390	A1	20020808	US 2001-931683	20010816

PRIORITY APPLN. INFO.: US 1999-183030P P 19990329
US 2000-533219 A2 20000323
OTHER SOURCE(S): MARPAT 136:325327
GI



I



II

AB The title compds. [I; W = O, S, SO, SO2; X = SR4, SOR4, SO2R4, etc.; Y = O, H2; Z = H, halo, OH, etc.; R = H, halo, CF3, etc.; Q = 5-tetrazolyl, COR1; R1 = OH, alkoxy, aryloxy, etc.; R2 = H, halo, alkyl; R3 = halo, alkyl; R4 = alkyl, aryl, heteroaryl, etc.; n = 0-4] which can be used to prevent and/or treat diseases assocd. with an imbalance of thyroid hormones, such as hypo- and hyper-thyroidism, obesity, osteoporosis and depression, were prepd. and formulated. E.g., a multi-step synthesis of II which showed IC50 of 0.17 nM in the T3 nuclear receptor binding assay, was given. The compds. I are, in particular, hypolipidemic agents which enhance the clearance of cholesterol from circulation, particularly the clearance of cholesterol in the form of low d. lipoproteins (LDL). The compds. I are useful for reducing total cholesterol plasma levels in mammals, in particular for reducing levels of LDL-cholesterol. Furthermore, such compds. also lower elevated lipoprotein (a) [Lp(a)] levels, an independent cardiovascular risk factor, in mammals. The compds. I can therefore be used for the prevention and/or treatment of occlusive cardiovascular conditions in which hyperlipidemia and hyperlipoproteinemia are implicated, such as atherosclerosis and coronary heart disease in mammals.

IT **298695-13-3P 298695-14-4P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of thyromimetic oxamic acids)

RN 298695-13-3 CAPLUS

CN Propanoic acid, 3-[[4-[3-[(4-fluorophenyl)sulfonyl]-4-hydroxyphenoxy]-3,5-dimethylphenyl]amino]-3-oxo- (9CI) (CA INDEX NAME)



RN 298695-14-4 CAPLUS

CN Butanoic acid, 4-[[4-[3-[(4-fluorophenyl)sulfonyl]-4-hydroxyphenoxy]-3,5-dimethylphenyl]amino]-4-oxo- (9CI) (CA INDEX NAME)



L3 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2001:730688 CAPLUS
DOCUMENT NUMBER: 135:288519
TITLE: Preparation of N-phenylmalonamic acid derivatives with thyroid receptor ligand activity
INVENTOR(S): Aspnes, Gary Erik; Chiang, Yuan-Ching Phoebe; Estep, Kimberly Gail
PATENT ASSIGNEE(S): Pfizer Products Inc., USA
SOURCE: PCT Int. Appl., 176 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001072692	A1	20011004	WO 2001-IB317	20010307
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1268404	A1	20030102	EP 2001-910082	20010307
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2001009625	A	20030422	BR 2001-9625	20010307
US 2001051657	A1	20011213	US 2001-819283	20010328
BG 107036	A	20030430	BG 2002-107036	20020826
NO 2002004639	A	20020927	NO 2002-4639	20020927

PRIORITY APPLN. INFO.: US 2000-193618P P 20000331
WO 2001-IB317 W 20010307
OTHER SOURCE(S): MARPAT 135:288519
GI



I



II

AB The title malonamates I [W = O, S, SO, SO2, CH2, CHF, CO, H2C:C, etc.; R0 = H, alkyl, alkyl substituted by cycloalkyl, heterocyclyl, Ph, halo, etc.; R1, R2, R3, R6 = H, halo, alkyl, F3C, alkoxy, cyano, etc.; R4 = alkyl, alkenyl, halo, cyano, alkoxy, HO, aryl, heteroaryl, etc.; R3R4 = (un)substituted carbocycle, heterocycle; R5 = HO, alkoxy, acyloxy, etc.; R7 = H, alkyl; R8, R9 = H, (un)substituted alkyl, aryl, halo; R10 = HO2C, carboxyalkyl, alkoxycarbonyl, alkoxycarbonylalkyl, carbamoyl, carbamoylalkyl, etc.] were prepd., possessed thyroid hormone receptor binding activities, and were useful in the treatment of obesity, overweight condition, hyperlipidemia, glaucoma, cardiac arrhythmias, skin disorders, thyroid disease, hypothyroidism, thyroid cancer, and related disorders and diseases such as diabetes mellitus, atherosclerosis, hypertension, coronary heart disease, congestive heart failure, hypercholesteremia, depression and osteoporosis. Thus, 4-(3-isopropyl-4-methoxyphenoxy)-3,5-dimethylnitrobenzene underwent successive BBr3-induced Me ether cleavage, hydrogenation in the presence of Pd/C, acylation by MeO2CCH2COCl, and sapon. to give the N-phenylmalonamic acid II.

IT **298695-13-3P**, N-[4-[3-(4-Fluorobenzenesulfonyl)-4-hydroxyphenoxy]-3,5-dimethylphenyl]malonamic acid **364331-31-7P**
364331-33-9P 364331-35-1P 364331-37-3P
364331-38-4P 364331-39-5P 364331-40-8P
364331-41-9P 364331-42-0P 364331-43-1P
364331-44-2P 364331-45-3P 364331-47-5P
364331-48-6P 364331-49-7P 364331-50-0P
364332-05-8P 364332-06-9P 364332-08-1P
364332-10-5P 364332-11-6P 364332-12-7P
364332-13-8P 364332-14-9P 364332-20-7P
364332-21-8P 364332-22-9P 364332-23-0P
364332-24-1P 364332-25-2P 364332-26-3P
364332-27-4P 364332-28-5P 364332-29-6P
364332-30-9P 364332-31-0P 364332-32-1P
364332-33-2P 364332-34-3P 364332-35-4P
364332-36-5P 364332-37-6P 364332-38-7P
364332-39-8P 364332-40-1P 364332-41-2P
364332-42-3P 364332-43-4P 364332-44-5P
364332-46-7P 364332-47-8P 364332-48-9P
364332-49-0P 364332-50-3P 364332-51-4P
364332-86-5P 364332-90-1P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of N-phenylmalonamates with thyroid receptor ligand activity)

RN 298695-13-3 CAPLUS

CN Propanoic acid, 3-[[4-[3-[(4-fluorophenyl)sulfonyl]-4-hydroxyphenoxy]-3,5-dimethylphenyl]amino]-3-oxo- (9CI) (CA INDEX NAME)



RN 364331-31-7 CAPLUS
CN Propanoic acid, 3-[[3,5-dichloro-4-[3-[(cyclopropylamino)sulfonyl]-4-hydroxyphenoxy]phenyl]amino]-3-oxo- (9CI) (CA INDEX NAME)



RN 364331-33-9 CAPLUS
CN Propanoic acid, 3-[[3,5-dichloro-4-[3-[(cyclobutylamino)sulfonyl]-4-hydroxyphenoxy]phenyl]amino]-3-oxo-, ethyl ester (9CI) (CA INDEX NAME)



RN 364331-35-1 CAPLUS
CN Propanoic acid, 3-[[3,5-dichloro-4-[3-[(cyclobutylamino)sulfonyl]-4-hydroxyphenoxy]phenyl]amino]-3-oxo- (9CI) (CA INDEX NAME)



RN 364331-37-3 CAPLUS
CN Propanoic acid, 3-[[3-chloro-4-[3-[(cyclobutylamino)sulfonyl]-4-hydroxyphenoxy]-5-methylphenyl]amino]-3-oxo-, ethyl ester (9CI) (CA INDEX NAME)



RN 364331-38-4 CAPLUS
CN Propanoic acid, 3-[[3-chloro-4-[3-[(cyclobutylamino)sulfonyl]-4-hydroxyphenoxy]-5-methylphenyl]amino]-3-oxo- (9CI) (CA INDEX NAME)



RN 364331-39-5 CAPLUS
CN Propanoic acid, 3-[[3,5-dichloro-4-[3-[(cyclopropylamino)sulfonyl]-4-hydroxy-5-(1-methylethyl)phenoxy]phenyl]amino]-3-oxo- (9CI) (CA INDEX NAME)



RN 364331-40-8 CAPLUS
CN Propanoic acid, 3-[[3,5-dichloro-4-[4-hydroxy-3-[[(1-methylethyl)amino]sulfonyl]phenoxy]phenyl]amino]-3-oxo- (9CI) (CA INDEX NAME)



RN 364331-41-9 CAPLUS
CN Propanoic acid, 3-[[4-[3-[(butylamino)sulfonyl]-4-hydroxyphenoxy]-3,5-dichlorophenyl]amino]-3-oxo- (9CI) (CA INDEX NAME)



RN 364331-42-0 CAPLUS
CN Propanoic acid, 3-[[3,5-dichloro-4-[3-[(heptylamino)sulfonyl]-4-hydroxyphenoxy]phenyl]amino]-3-oxo- (9CI) (CA INDEX NAME)



RN 364331-43-1 CAPLUS
CN Propanoic acid, 3-[[3,5-dichloro-4-[3-[[(4-fluorophenyl)amino]sulfonyl]-4-hydroxyphenoxy]phenyl]amino]-3-oxo- (9CI) (CA INDEX NAME)



RN 364331-44-2 CAPLUS
CN Propanoic acid, 3-[[4-[3-[(cyclobutylamino)sulfonyl]-4-hydroxyphenoxy]-3,5-dimethylphenyl]amino]-3-oxo- (9CI) (CA INDEX NAME)



RN 364331-45-3 CAPLUS
CN Propanoic acid, 3-[[4-[3-[(cyclopropylamino)sulfonyl]-4-hydroxyphenoxy]-3,5-dimethylphenyl]amino]-3-oxo- (9CI) (CA INDEX NAME)



RN 364331-47-5 CAPLUS
CN Propanoic acid, 3-[[4-[3-[(cyclopentylamino)sulfonyl]-4-hydroxyphenoxy]-3,5-dimethylphenyl]amino]-3-oxo- (9CI) (CA INDEX NAME)



RN 364331-48-6 CAPLUS
CN Propanoic acid, 3-[[4-[3-[(cyclohexylamino)sulfonyl]-4-hydroxyphenoxy]-3,5-dimethylphenyl]amino]-3-oxo- (9CI) (CA INDEX NAME)



RN 364331-49-7 CAPLUS
CN Propanoic acid, 3-[[3,5-dichloro-4-[3-[(cyclopentylamino)sulfonyl]-4-hydroxyphenoxy]phenyl]amino]-3-oxo- (9CI) (CA INDEX NAME)



RN 364331-50-0 CAPLUS
CN Propanoic acid, 3-[[3,5-dichloro-4-[3-[(cyclohexylamino)sulfonyl]-4-hydroxyphenoxy]phenyl]amino]-3-oxo- (9CI) (CA INDEX NAME)



RN 364332-05-8 CAPLUS
CN Propanoic acid, 3-[[3,5-dichloro-4-[3-[(4-fluorophenyl)sulfonyl]-4-hydroxyphenoxy]phenyl]amino]-3-oxo- (9CI) (CA INDEX NAME)



RN 364332-06-9 CAPLUS
CN Propanoic acid, 3-[[3,5-dichloro-4-[3-[(4-fluorophenyl)sulfonyl]-4-hydroxyphenoxy]phenyl]amino]-3-oxo-, ethyl ester (9CI) (CA INDEX NAME)



RN 364332-08-1 CAPLUS
CN Propanoic acid, 3-[[3-chloro-4-[3-[(4-fluorophenyl)sulfonyl]-4-hydroxyphenoxy]-5-methylphenyl]amino]-3-oxo- (9CI) (CA INDEX NAME)



RN 364332-10-5 CAPLUS
CN Propanoic acid, 3-[[4-[3-[(4-fluorophenyl)sulfonyl]-4-hydroxyphenoxy]-3,5-dimethylphenyl]amino]-2-methyl-3-oxo- (9CI) (CA INDEX NAME)



RN 364332-11-6 CAPLUS
CN Propanoic acid, 3-[[3-chloro-4-[3-[(4-fluorophenyl)sulfonyl]-4-hydroxyphenoxy]-5-methylphenyl]amino]-2-methyl-3-oxo-, methyl ester (9CI) (CA INDEX NAME)



RN 364332-12-7 CAPLUS
CN Propanoic acid, 3-[[3-chloro-4-[3-[(4-fluorophenyl)sulfonyl]-4-hydroxyphenoxy]-5-methylphenyl]amino]-2-methyl-3-oxo- (9CI) (CA INDEX NAME)



RN 364332-13-8 CAPLUS
CN Propanoic acid, 3-[[3,5-dichloro-4-[3-[(4-fluorophenyl)sulfonyl]-4-hydroxyphenoxy]phenyl]amino]-2-methyl-3-oxo-, methyl ester (9CI) (CA INDEX NAME)



RN 364332-14-9 CAPLUS
CN Propanoic acid, 3-[[3,5-dichloro-4-[3-[(4-fluorophenyl)sulfonyl]-4-hydroxyphenoxy]phenyl]amino]-2-methyl-3-oxo- (9CI) (CA INDEX NAME)



RN 364332-20-7 CAPLUS
CN Propanoic acid, 3-[[3,5-dichloro-4-[3-[(cyclopropylmethyl)sulfonyl]-4-hydroxyphenoxy]phenyl]amino]-3-oxo- (9CI) (CA INDEX NAME)



RN 364332-21-8 CAPLUS
CN Propanoic acid, 3-[[3-chloro-4-[3-[(cyclobutylmethyl)sulfonyl]-4-hydroxyphenoxy]-5-methylphenyl]amino]-3-oxo-, methyl ester (9CI) (CA INDEX NAME)



RN 364332-22-9 CAPLUS
CN Propanoic acid, 3-[[3-chloro-4-[3-[(cyclopropylmethyl)sulfonyl]-4-hydroxyphenoxy]-5-methylphenyl]amino]-3-oxo-, methyl ester (9CI) (CA INDEX NAME)



RN 364332-23-0 CAPLUS
CN Propanoic acid, 3-[[3-chloro-4-[3-[(cyclobutylmethyl)sulfonyl]-4-hydroxyphenoxy]-5-methylphenyl]amino]-3-oxo- (9CI) (CA INDEX NAME)



RN 364332-24-1 CAPLUS
CN Propanoic acid, 3-[[3-chloro-4-[3-[(cyclopropylmethyl)sulfonyl]-4-hydroxyphenoxy]-5-methylphenyl]amino]-3-oxo-, ethyl ester (9CI) (CA INDEX NAME)



RN 364332-25-2 CAPLUS
CN Propanoic acid, 3-[[3-chloro-4-[3-[(cyclobutylmethyl)sulfonyl]-4-hydroxyphenoxy]-5-methylphenyl]amino]-3-oxo-, ethyl ester (9CI) (CA INDEX NAME)



RN 364332-26-3 CAPLUS
CN Propanoic acid, 3-[[3-chloro-4-[3-[(cyclopropylmethyl)sulfonyl]-4-hydroxyphenoxy]-5-methylphenyl]amino]-3-oxo- (9CI) (CA INDEX NAME)



RN 364332-27-4 CAPLUS
CN Propanoic acid, 3-[[3,5-dichloro-4-[4-hydroxy-3-(methylsulfonyl)phenoxy]phenyl]amino]-3-oxo-, methyl ester (9CI) (CA INDEX NAME)



RN 364332-28-5 CAPLUS
CN Propanoic acid, 3-[[3,5-dichloro-4-[3-(ethylsulfonyl)-4-hydroxyphenoxy]phenyl]amino]-3-oxo- (9CI) (CA INDEX NAME)



RN 364332-29-6 CAPLUS
CN Propanoic acid, 3-[[3,5-dichloro-4-[4-hydroxy-3-(methylsulfonyl)phenoxy]phenyl]amino]-3-oxo- (9CI) (CA INDEX NAME)



RN 364332-30-9 CAPLUS
CN Propanoic acid, 3-[[4-[3-[(cyclobutylmethyl)sulfonyl]-4-hydroxyphenoxy]-3,5-dimethylphenyl]amino]-3-oxo-, ethyl ester (9CI) (CA INDEX NAME)



RN 364332-31-0 CAPLUS
CN Propanoic acid, 3-[[4-[3-[(cyclobutylmethyl)sulfonyl]-4-hydroxyphenoxy]-3,5-dimethylphenyl]amino]-3-oxo-, methyl ester (9CI) (CA INDEX NAME)



RN 364332-32-1 CAPLUS
CN Propanoic acid, 3-[[4-[3-[(cyclobutylmethyl)sulfonyl]-4-hydroxyphenoxy]-3,5-dimethylphenyl]amino]-3-oxo- (9CI) (CA INDEX NAME)



RN 364332-33-2 CAPLUS
CN Propanoic acid, 3-[[3,5-dichloro-4-[3-[(cyclobutylmethyl)sulfonyl]-4-hydroxyphenoxy]phenyl]amino]-3-oxo-, ethyl ester (9CI) (CA INDEX NAME)



RN 364332-34-3 CAPLUS
CN Propanoic acid, 3-[[3,5-dichloro-4-[3-[(cyclobutylmethyl)sulfonyl]-4-hydroxyphenoxy]phenyl]amino]-3-oxo- (9CI) (CA INDEX NAME)



RN 364332-35-4 CAPLUS
CN Propanoic acid, 3-[[4-[3-(cyclopentylsulfonyl)-4-hydroxyphenoxy]-3,5-dimethylphenyl]amino]-3-oxo- (9CI) (CA INDEX NAME)



RN 364332-36-5 CAPLUS
CN Propanoic acid, 3-[[4-[3-[(cyclopentylmethyl)sulfonyl]-4-hydroxyphenoxy]-3,5-dimethylphenyl]amino]-3-oxo- (9CI) (CA INDEX NAME)



RN 364332-37-6 CAPLUS
CN Propanoic acid, 3-[[4-[3-[(cyclobutylmethyl)sulfonyl]-4-hydroxyphenoxy]-3,5-dimethylphenyl]amino]-2-methyl-3-oxo-, methyl ester (9CI) (CA INDEX NAME)



RN 364332-38-7 CAPLUS
CN Propanoic acid, 3-[[4-[3-[(cyclobutylmethyl)sulfonyl]-4-hydroxyphenoxy]-3,5-dimethylphenyl]amino]-2-methyl-3-oxo- (9CI) (CA INDEX NAME)



RN 364332-39-8 CAPLUS
CN Propanoic acid, 3-[[4-[3-[(cyclopentylmethyl)sulfonyl]-4-hydroxyphenoxy]-3,5-dimethylphenyl](1-methylethyl)amino]-3-oxo- (9CI) (CA INDEX NAME)



RN 364332-40-1 CAPLUS
CN Propanoic acid, 3-[[3-chloro-4-[3-[(cyclohexylmethyl)sulfonyl]-4-hydroxyphenoxy]-5-methylphenyl]amino]-3-oxo- (9CI) (CA INDEX NAME)



RN 364332-41-2 CAPLUS
CN Propanoic acid, 3-[[3-chloro-4-[3-[(cyclobutylmethyl)sulfonyl]-4-hydroxyphenoxy]-5-methylphenyl]amino]-2-methyl-3-oxo-, methyl ester (9CI) (CA INDEX NAME)



RN 364332-42-3 CAPLUS
CN Propanoic acid, 3-[[3-chloro-4-[3-[(cyclobutylmethyl)sulfonyl]-4-hydroxyphenoxy]-5-methylphenyl]amino]-2-methyl-3-oxo- (9CI) (CA INDEX NAME)



RN 364332-43-4 CAPLUS
CN Propanoic acid, 3-[[3,5-dichloro-4-[3-[(cyclopentylmethyl)sulfonyl]-4-hydroxyphenoxy]phenyl]amino]-3-oxo- (9CI) (CA INDEX NAME)



RN 364332-44-5 CAPLUS
CN Propanoic acid, 3-[[3,5-dichloro-4-[3-[(cyclohexylmethyl)sulfonyl]-4-hydroxyphenoxy]phenyl]amino]-3-oxo- (9CI) (CA INDEX NAME)



RN 364332-46-7 CAPLUS
CN Propanoic acid, 3-[[3-chloro-4-[3-[(cyclopentylmethyl)sulfonyl]-4-hydroxyphenoxy]-5-methylphenyl]amino]-3-oxo- (9CI) (CA INDEX NAME)



RN 364332-47-8 CAPLUS
CN Propanoic acid, 3-[[4-[3-[(cyclohexylmethyl)sulfonyl]-4-hydroxyphenoxy]-3,5-dimethylphenyl]amino]-3-oxo- (9CI) (CA INDEX NAME)



RN 364332-48-9 CAPLUS
CN Propanoic acid, 3-[[4-[3-[(cyclopentylmethyl)sulfonyl]-4-hydroxyphenoxy]-3-methylphenyl]amino]-3-oxo- (9CI) (CA INDEX NAME)



RN 364332-49-0 CAPLUS
CN Propanoic acid, 3-[[4-[3-[(cyclohexylmethyl)sulfonyl]-4-hydroxyphenoxy]phenyl]amino]-3-oxo- (9CI) (CA INDEX NAME)



RN 364332-50-3 CAPLUS
CN Propanoic acid, 3-[[4-[3-[(cyclobutylmethyl)sulfonyl]-4-hydroxyphenoxy]-3-methylphenyl]amino]-3-oxo- (9CI) (CA INDEX NAME)



RN 364332-51-4 CAPLUS
CN Propanoic acid, 3-[[3-chloro-4-[3-(cyclopentylsulfonyl)-4-hydroxyphenoxy]-5-methylphenyl]amino]-3-oxo- (9CI) (CA INDEX NAME)



RN 364332-86-5 CAPLUS
CN Propanoic acid, 3-[[3-chloro-4-[3-[(4-fluorophenyl)sulfonyl]-4-hydroxyphenoxy]-5-methylphenyl]amino]-3-oxo-, methyl ester (9CI) (CA INDEX NAME)



RN 364332-90-1 CAPLUS
CN Propanoic acid, 3-[[3,5-dichloro-4-[3-(ethylsulfonyl)-4-hydroxyphenoxy]phenyl]amino]-3-oxo-, methyl ester (9CI) (CA INDEX NAME)



IT **364331-28-2P 364332-04-7P 364332-07-0P**
364332-09-2P 364332-19-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of N-phenylmalonamates with thyroid receptor ligand activity)

RN 364331-28-2 CAPLUS
CN Propanoic acid, 3-[[3,5-dichloro-4-[3-[(cyclopropylamino)sulfonyl]-4-hydroxyphenoxy]phenyl]amino]-3-oxo-, methyl ester (9CI) (CA INDEX NAME)



RN 364332-04-7 CAPLUS
CN Propanoic acid, 3-[[3,5-dichloro-4-[3-[(4-fluorophenyl)sulfonyl]-4-hydroxyphenoxy]phenyl]amino]-3-oxo-, methyl ester (9CI) (CA INDEX NAME)



RN 364332-07-0 CAPLUS
CN Propanoic acid, 3-[[4-[3-[(4-fluorophenyl)sulfonyl]-4-hydroxyphenoxy]-3,5-dimethylphenyl]amino]-3-oxo-, methyl ester (9CI) (CA INDEX NAME)



RN 364332-09-2 CAPLUS
CN Propanoic acid, 3-[[4-[3-[(4-fluorophenyl)sulfonyl]-4-hydroxyphenoxy]-3,5-dimethylphenyl]amino]-2-methyl-3-oxo-, methyl ester (9CI) (CA INDEX NAME)



RN 364332-19-4 CAPLUS
CN Propanoic acid, 3-[[3,5-dichloro-4-[3-[(cyclopropylmethyl)sulfonyl]-4-hydroxyphenoxy]phenyl]amino]-3-oxo-, ethyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2000:707138 CAPLUS
DOCUMENT NUMBER: 133:266609
TITLE: Preparation of (4-phenoxyphenyl)oxamic acid derivatives and analogs as hypolipidemics
INVENTOR(S): Kukkola, Paivi Jaana
PATENT ASSIGNEE(S): Novartis A.-G., Switz.; Novartis-Erfindungen
SOURCE: PCT Int. Appl., 53 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000058279	A1	20001005	WO 2000-EP2683	20000327

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE,

Applicant 5

SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA,
ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE,
DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF,
CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

NZ 514062	A	20010928	NZ 2000-514062		20000327
EP 1165502	A1	20020102	EP 2000-922557		20000327
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO					
BR 2000009431	A	20020108	BR 2000-9431		20000327
JP 2002540189	T2	20021126	JP 2000-607982		20000327
NO 2001004702	A	20010927	NO 2001-4702		20010927
PRIORITY APPLN. INFO.:			US 1999-183030P	P	19990329
			US 1999-280105	A	19990329
			WO 2000-EP2683	W	20000327

OTHER SOURCE(S): MARPAT 133:266609

GI



I



II

AB The title compds. (I) [wherein W = O, S, S(O) or SO2; X = SR4, S(O)R4, SO2R4, SO2NR5R6, or CONR5R6; Y = O or H2; Z = H, halogen, OH, or (un)substituted (ar)alkoxy, acyloxy, or alkoxycarbonyloxy; R = H, halogen, CF3, or (cyclo)alkyl; R1 = OH, (un)substituted (cyclo)alkoxy, (hetero)aryloxy, or (hetero)aralkoxy, or -NR5R6; R2 = H, halogen, or alkyl; R3 = halogen or alkyl; R4 is (un)substituted (ar)alkyl, (hetero)aryl, or heteroaralkyl; R5, R6, and R7 = independently H, (un)substituted (cyclo)alkyl, (hetero)aryl, or (hetero)aralkyl; or R5 and R6 combined = alkylene optionally interrupted by O, S, S(O), SO2, or NR7 which together with the nitrogen atom to which they are attached form a 5- to 7-membered ring; n = 0-4] were prepd. I demonstrated potent binding to the triiodothyronine (T3) nuclear receptor, which is indicative of upregulation of LDL receptor activity and enhancement of the clearance of LDL-cholesterol from the circulation. I also reduced lipoprotein (a) levels and are useful for the treatment and prevention of occlusive cardiovascular conditions implicated by Lp(a). For example, 2-(4-fluorobenzensulfonyl)benzene-1,4-diol (prepn. given) was coupled with 4-chloro-3,5-dimethylnitrobenzene in the presence of NaH, and the product reduced using Pd/C. Amidation with di-Et oxalate, followed by deesterification, gave II. In an in vitro T3 nuclear receptor binding assay using Sprague-Dawley rat liver nuclei and plasma membrane prepns., II gave an IC50 of 0.17 nM. II significantly lowered serum cholesterol at a daily dose of about 20 .mu.g/kg p.o. in male Sprague-Dawley rats and about 10 .mu.g/kg p.o. in normocholesterolemic dogs. Lp(a) levels in

normolipemic cynomolgus monkeys were lowered by about 40% after a 4 wk treatment with II at a daily oral dose of 75 .mu.g/kg. Thus, I are useful in the prevention and treatment of diseases assocd. with an imbalance of thyroid hormones, such as hypo- and hyperthyroidism, obesity, osteoporosis, and depression, and for lowering LDL cholesterol and Lp(a) levels.

IT **298695-13-3P**, N-[4-[3-(4-Fluorobenzenesulfonyl)-4-hydroxyphenoxy]-3,5-dimethylphenyl]malonamic acid **298695-14-4P**, N-[4-[3-(4-Fluorobenzenesulfonyl)-4-hydroxyphenoxy]-3,5-dimethylphenyl]succinamic acid
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of (4-phenoxyphenyl)oxamic acid derivs. and analogs as hypolipidemics by coupling phenols with 4-chloronitrobenzenes, redn. to the amines, and amidation with oxalates)

RN 298695-13-3 CAPLUS
CN Propanoic acid, 3-[[4-[3-[(4-fluorophenyl)sulfonyl]-4-hydroxyphenoxy]-3,5-dimethylphenyl]amino]-3-oxo- (9CI) (CA INDEX NAME)



RN 298695-14-4 CAPLUS
CN Butanoic acid, 4-[[4-[3-[(4-fluorophenyl)sulfonyl]-4-hydroxyphenoxy]-3,5-dimethylphenyl]amino]-4-oxo- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d his

(FILE 'HOME' ENTERED AT 14:57:09 ON 17 JUN 2003)

FILE 'REGISTRY' ENTERED AT 14:57:18 ON 17 JUN 2003
L1 STRUCTURE UPLOADED
L2 64 S L1 FUL

FILE 'CAPLUS' ENTERED AT 14:58:07 ON 17 JUN 2003
L3 5 S L2

=> log y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	23.10	171.46

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL

09/ 966,960

	ENTRY	SESSION
CA SUBSCRIBER PRICE	-3.26	-3.26

STN INTERNATIONAL LOGOFF AT 14:58:54 ON 17 JUN 2003